Wockhardt gained 2% after a UK journal spotlighted its drug Zaynich's success in a critical U.S. transplant case. Analyst Sameer Pande sees long-term strength, with support at Rs 1,520-1,600. Resistance looms at Rs 1,780-1,880. RSI on monthly charts is 75. Retail sentiment is 'neutral' on Stocktwits. The stock is up 17.5% YTD.